2128 POSTER PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT): correlation with clinical outcome

S.Gori; V.De Angelis; A.Sidoni; M.Colozza; I.Ferri; D.Fenocchio; V.Ludovini; C.Basurto; P.Anastasi; L.Crinó

首页> 外文期刊>European Journal of Cancer Supplements >2128 POSTER PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT): correlation with clinical outcome

【24h】

2128 POSTER PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT): correlation with clinical outcome

机译：接受曲妥珠单抗（T）±化疗（CT）治疗的HER2阳性（HER2 +）转移性乳腺癌（MBC）患者（pts）的免疫组织化学（IHC）检测2128 POSTER PTEN，EGFR，MAPK和Akt状态

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
S.Gori; V.De Angelis; A.Sidoni; M.Colozza; I.Ferri; D.Fenocchio; V.Ludovini; C.Basurto; P.Anastasi; L.Crinó;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. [J] . Gori S, Sidoni A, Colozza M, Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第4期

机译：免疫组化检测EGFR，pMAPK，pAkt和PTEN状态：与曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者的临床结局相关。
2. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab [J] . S. Gori1* A. Sidoni2 M. Colozza1 I. Ferri2 M. G. Mameli2 D. Fenocchio3 L. Stocchi1 J. Foglietta1 V. Ludovini1 E. Minenza1 V. De Angelis4 and L. Crinò1 Annals of Oncology . 2009,第4期

机译：免疫组化检测EGFR，pMAPK，pAkt和PTEN状态：与曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者的临床结局相关
3. 5089 Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T)+/- chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC) [J] . S.Gori, A.Sidoni, M.Colozza, European Journal of Cancer Supplements . 2009,第2期

机译：5089使用曲妥珠单抗（T）+/-化疗（CT）治疗并通过免疫组织化学（IHC）过表达HER3的HER2阳性（HER2 +）转移性乳腺癌（MBC）患者（pts）的总体生存期缩短
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab [O] . PETER GRELL, PAVEL FABIAN, MARTA KHOYLOU, -1

机译：曲妥珠单抗治疗HER2阳性转移性乳腺癌患者Akt表达和区隔预测临床结局
6. PTEN, PIK3CA, p-AKT, and p-p70S6K Status: Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer [O] . Esteva, Francisco J., Guo, Hua, Zhang, Siyuan, 2010

机译：PTEN，PIK3CA，p-AKT和p-p70S6K状态：与曲妥珠单抗反应和HER2阳性转移性乳腺癌患者生存率相关

2128 POSTER PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT): correlation with clinical outcome

著录项

相似文献

相关主题

期刊订阅